Is Loblaws stock a buy right now?

Our system shows a Stock Grade of B+ (BUY) and a Company Rating of A (Buy) as of Feb 24, 2026. The case rests on defensive demand in grocery and pharmacy, plus a C$2.4B expansion plan. As always, align any purchase with your risk tolerance and time horizon.

What drove Loblaw earnings in Q4?

Q4 revenue was C$16.38B (including a 13th week) and adjusted EPS was C$0.67. Strength came from discount banners, pharmacies, and private‑label products as Canadians sought value. These factors supported mix and margins, helping both sales and profit trends in the quarter.

What is the TSX L share price and range today?

Loblaws stock last traded near C$67.52. Today’s range was C$66.69 to C$69.59, and the 52‑week range is C$43.78 to C$68.94. Technical indicators show RSI at 43.12 and CCI at -219, suggesting cautious momentum with potential stabilization if the price holds above the mid‑Bollinger band.

What is Loblaw’s 2026 outlook?

Management guided adjusted EPS growth to the high single digits for 2026. The plan leans on discount formats, pharmacy expansion under Shoppers Drug Mart, and private‑label strength, supported by a C$2.4B capital program to open 70 stores and enhance distribution capacity.

How does the Shoppers Drug Mart expansion help growth?

Pharmacies add frequent trips, steady prescription revenue, and front‑store basket potential. Expanding Shoppers Drug Mart supports traffic and mix, while distribution upgrades should improve availability. Together, these steps can support margins, cash flow, and the overall investment case for Loblaws stock in Canada.

Global Market Insights

L.TO Stock Today: Q4 EPS Up, $2.4B Expansion Plan — February 25

ByHuzaifa Zahoor February 26, 2026

Loblaws stock is in focus today after Loblaw reported Q4 revenue of C$16.38B, boosted by a 13th week, and adjusted EPS of C$0.67. Management guided 2026 EPS growth to the high single digits and announced a C$2.4B plan to open 70 stores and enhance distribution. The strategy leans on discount banners, pharmacies, and private‑label strength to meet value‑seeking demand. On the TSX, L.TO last traded near C$67.52, within a 52‑week range of C$43.78 to C$68.94. We break down what this means for Canadian investors.